Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: It is important to determine the noninvasive parameters of histological features in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to investigate the value of genetic variations as surrogate markers of histological features. Methods: The parameters that affected the histological features of NAFLD were investigated in 211 Japanese patients with biopsy-proven NAFLD. The relationships between genetic variations in PNPLA3 rs738409 or TM6SF2 rs58542926 and histological features were analyzed. Furthermore, the impact of genetic variations that affected the pathological criteria for the diagnosis of nonalcoholic steatohepatitis (NASH) (Matteoni classification and NAFLD activity score) was evaluated. Results: The fibrosis stage of PNPLA3 GG was significantly more progressive than that of CG by multiple comparisons. Multivariate analysis identified PNPLA3 genotypes as predictors of fibrosis of stage 2 or more, but the impact tended to decrease at stage 3 or greater. There were no significant differences among the histological features of the three genotypes of TM6SF2. PNPLA3 genotypes partly affected the definition of NASH by the NAFLD activity score, but TM6SF2 genotypes did not affect the definition of NASH. Conclusions: In Japanese patients with biopsy-proven NAFLD, PNPLA3 genotypes may partly affect histological features, including stage of fibrosis, but the TM6SF2 genotype does not affect histological features.
Abstract
Background/Aims: It is important to determine the noninvasive parameters of histological features in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to investigate the value of genetic variations as surrogate markers of histological features. Methods: The parameters that affected the histological features of NAFLD were investigated in 211 Japanese patients with biopsy-proven NAFLD. The relationships between genetic variations in PNPLA3 rs738409 or TM6SF2 rs58542926 and histological features were analyzed. Furthermore, the impact of genetic variations that affected the pathological criteria for the diagnosis of nonalcoholic steatohepatitis (NASH) (Matteoni classification and NAFLD activity score) was evaluated. Results: The fibrosis stage of PNPLA3 GG was significantly more progressive than that of CG by multiple comparisons. Multivariate analysis identified PNPLA3 genotypes as predictors of fibrosis of stage 2 or more, but the impact tended to decrease at stage 3 or greater. There were no significant differences among the histological features of the three genotypes of TM6SF2. PNPLA3 genotypes partly affected the definition of NASH by the NAFLD activity score, but TM6SF2 genotypes did not affect the definition of NASH. Conclusions: In Japanese patients with biopsy-proven NAFLD, PNPLA3 genotypes may partly affect histological features, including stage of fibrosis, but the TM6SF2 genotype does not affect histological features.
참고문헌 (26)
- Angulo P, "Nonalcoholic fatty liver disease", N Engl J Med, 346, pp.1221~1231 (2002)
- Williams R, "Global challenges in liver disease", Hepatology, 44, pp.521~526 (2006)
- Torres DM, "Diagnosis and therapy of nonalcoholic steatohepatitis", Gastroenterology, 134, pp.1682~1698 (2008)
- Vuppalanchi R, "Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management", Hepatology, 49, pp.306~317 (2009)
- Kawamura Y, "Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma", Am J Gastroenterol, 107, pp.253~261 (2012)
- Sumida Y, "Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease", nonalcoholic steatohepatitis, 2014, pp.20, 475~485
- Kleiner DE, "Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research", Semin Liver Dis, 32, pp.3~13 (2012)
- Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
- Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial", Lancet, 385, pp.956~965 (2015)
- Sookoian S, "The genetic epidemiology of nonalcoholic fatty liver disease: toward a personalized medicine", Clin Liver Dis, 16, pp.467~485 (2012)
- Romeo S, "Genetic variation in PNPLA3confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
- Sookoian S, "A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity", J Lipid Res, 50, pp.2111~2116 (2009)
- Hotta K, "Association of the rs738409polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease", BMC Med Genet, 11, pp.172~ (2010)
- Kawaguchi T, "Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese", PLoS One, 7, pp.e38322~ (2012)
- Kozlitina J, "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 46, pp.352~356 (2014)
- Liu YL, "TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease", Nat Commun, 5, pp.4309~ (2014)
- Wong VW, "Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese", J Hepatol, 61, pp.708~709 (2014)
- Sookoian S, "Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity", Hepatology, 61, pp.515~525 (2015)
- Brunt EM, "Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions", Am J Gastroenterol, 94, pp.2467~2474 (1999)
- Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
- Matteoni CA, "Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
- Pearson TA, "AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee", Circulation, 106, pp.388~391 (2002)
- Angulo P, "The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
- Harrison SA, "Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease", Gut, 57, pp.1441~1447 (2008)
- Sumida Y, "A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease", J Gastroenterol, 46, pp.257~268 (2011)
- Kessoku T, "Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease", World J Gastroenterol, 20, pp.10108~10114 (2014)